|
Driessen 2008[68], Radboud University Registry, The Netherlands (Driessen 2009[69])
|
Efficacy and tolerability of etenercept and efalizumab
|
Registry
|
118
|
Psoriasis
|
24 weeks
|
|
Fortune 2003[6], PUVA Study, UK and Ireland
|
Role of psychological distress on PUVA treatment outcomes
|
Cohort
|
112
|
Plaque psoriasis (chronic)
|
2 years
|
|
Lecha 2005[70], Spanish tacalcitol ointment study
|
Efficacy and tolerability of tacalcitol
|
Cohort
|
556
|
Psoriasis (moderate)
|
2 months
|
|
Naldi 2008[71], Psocare, Italy
|
Effect of BMI on clinical response to systemic treatment
|
Cohort
|
2368
|
Plaque psoriasis
|
3 years
|
|
Paul 2003[72] Cyclosporine study, Europe and Canada
|
Incidence of malignancies in cyclosporine treated patients
|
Cohort
|
1252
|
psoriasis - severe
|
5 years
|
|
Wahl 2005[73], Climate therapy study, Norway
|
Effectiveness of climate therapy
|
Cohort
|
286
|
Psoriasis
|
8 months
|
|
Heiberg 2008[74], Norwegian register of disease modifying anti-rheumatic drugs, (Heiberg 2007[75])
|
Comparative effectiveness of TNF inhibitors vs. methotrexate monotherapy
|
Registry
|
526
|
Psoriatic arthritis
|
1 year
|
|
Kristensen 2008[76], South Swedish Arthritis Treatment Group register, (Gulfe 2009[77], Geborek 2002[78], Kristensen 2006[79])
|
Efficacy, utility and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab)
|
Registry
|
261
|
Psoriatic arthritis
|
7 years
|
|
Sparado 1997[80], Cyclosporin Study, Italy
|
Probability of continuing to take cyclosporine vs. other DMARDS
|
Cohort
|
172
|
Psoriatic arthritis
|
10 years
|
|
Saad 2009[81], British Society for Rheumatology Biologics Register, (Harrison 2009[82], Silman 2003[83])
|
Effectiveness and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab)
|
Registry
|
566
|
RA, psoriasis, psoriatic arthritis
|
1 year
|
|
Non-treatment related observational studies
|
|
Carrascosa 2006[84], EPIDERMA cost of illness, Spain
|
Direct and indirect cost; relationship between cost and severity
|
Cohort
|
797
|
Psoriasis
|
1 year
|
|
Colombo 2008[11], Cost of illness, Italy
|
Direct and indirect cost; HRQOL; relationship between cost, HRQOL and severity
|
Cohort
|
150
|
Moderate to severe plaque psoriasis
|
3 months
|
|
Schmid-ott 2005[85], Bad Bentheim Rehabilitation Hospital, Germany
|
Relationship between the degree of stigmatisation and gender, skin symptoms, PASI and SPASI
|
Cohort
|
166
|
Psoriasis
|
1 year
|
|
Ali 2007[86], Husted 2007[2], Gladman 2009[16], Rohekar 2008[87], Toronto PsA clinic, Canada, (Chandran 2007[88], Gladman 1995[89], Gladman 1998[90], Gladman 1999 [91], Gladman 2001[92], Husted 2005[93], Wong 1997[94])
|
(1) Mortality associated with PsA; (2) relationship between physical functioning, disease activity and joint damage; (3) CVD associated with PsA; (4) malignancies associated with PsA
|
Cohort
|
382 to 680
|
Psoriatic arthritis
|
26 years
|
|
Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96])
|
Clinical presentation, outcome and prognosis of early PsA
|
Cohort
|
129
|
Early psoriatic arthritis
|
2 years
|
|
Lindqvist 2008[97], SwePsA registry, Sweden, (Svensson 2002[98])
|
Factors associated with disease progression; outcome of treated and non-treated groups, comparison of outcomes with RA patients
|
Registry
|
135
|
Early psoriatic arthritis
|
2 years
|
